Diss. (sammanfattning) Umeå : Univ., 2007. / Härtill 4 uppsatser.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2009. / Title from PDF title page (viewed on Sept. 10, 2009). Includes bibliographical references.

Objetivo: A glicogênio sintase quinase-3 beta (GSK-3B) é uma enzima presente em diversos sistemas biológicos e está envolvida na fisiopatologia de vários transtornos neuropsiquiátricos, incluindo o transtorno bipolar. No entanto, estudos in vivo da GSK-3B que envolvam pacientes bipolares são escassos. O objetivo do presente estudo foi avaliar a atividade da GSK-3B em plaquetas de pacientes idosos com transtorno bipolar em tratamento, em comparação com idosos saudáveis não medicados. Métodos: Foram obtidas amostras de plaquetas de 63 idosos (transtorno bipolar=31, grupo controle=32). A atividade enzimática foi estimada pela razão entre a expressão da forma fosforilada (inativa) da GSK-3B em relação à expressão de ambas as formas (ativa e inativa) da enzima (GSK-3B total), que fornece uma estimativa inversa da atividade enzimática (um aumento da razão indica menor atividade da GSK-3B). A intensidade dos sintomas foi avaliada pela Escala de Depressão de Hamilton de 21 itens e pela Escala de Mania de Young, e o desempenho cognitivo foi avaliado pelo Cambridge Cognitive Test e pelo Mini- Exame do Estado Mental. Resultados: A forma fosforilada da GSK-3B (fosfo-GSK-3B) e a razão da GSK-3B estavam elevadas em pacientes com transtorno bipolar, quando comparadas aos idosos do grupo controle (p=0,018 e p=0,016, respectivamente). Na avaliação por subgrupos, observaram-se níveis da fosfo-GSK-3B e da razão da GSK-3B mais elevados nos pacientes com transtorno bipolar em uso de lítio, quando comparados aos controles (p=0,030 e p=0,023, respectivamente), mas não quando comparados aos pacientes com transtorno bipolar que não usavam lítio. O uso das demais medicações avaliadas (anticonvulsivantes, antipsicóticos, antidepressivos e 16 benzodiazepínicos) não estava associado a diferenças na fosfo-GSK-3B ou na razão da GSK-3B, quando comparado aos controles. Conclusões: A atividade da GSK-3B está diminuída no presente grupo de idosos com transtorno bipolar em tratamento medicamentoso. A ausência de um grupo de pacientes com transtorno bipolar não medicado, e a não uniformidade das medicações utilizadas não nos permitem afirmar se essa redução se deve à características da doença bipolar em si ou seria influência dos medicamentos utilizados / Objective: Glycogen synthase kinase-3 beta (GSK-3B) is an important enzyme present in various biological systems and it is involved in the pathophysiology of many prevalent neuropsychiatric diseases, including bipolar disorder. However, human studies addressing GSK-3B activity in vivo are scarce. The aim of the present study was to evaluate GSK-3B activity in platelets of elderly patients with bipolar disorder undergoing clinical treatment as compared to healthy older adults unmedicated. Methods: Platelets samples where obtained from 63 older adults (bipolar disorder=31, comparison group=32). Enzymatic activity was estimated by means of the ratio between the expression of the phosphorylated (inactive) form of GSK-3B to the expression of both forms (active and inactive) of the enzyme (total GSK-3B), yielding an inverse estimate of enzymatic activity (higher ratio indicating lower GSK- 3B activity). The magnitude of mood symptoms was evaluated by the Hamilton Depression Scale and Young Mania Rating Scale, and the cognitive performance was assessed by the Cambridge Cognitive Test and the Mini-Mental State Examination. Results: The phosphorylated form of GSK-3B (phospho-GSK-3B) and the GSK-3B ratio were elevated in patients with bipolar disorder as compared to healthy controls (P=.018 and P=.016, respectively). When analyzed by subgroups, phospho-GSK-3B and the GSK-3B ratio were elevated in bipolar patients undergoing lithium treatment as compared to healthy controls (P=.030 and P=.023, respectively), but not when compared to bipolar patients without lithium treatment. The use of other drugs evaluated (anticonvulsants, antipsychotics, antidepressants and benzodiazepines) was not associated with distinct values of either phospho-GSK-3B or GSK-3B ratio, when compared to controls. 18 Conclusions: GSK-3B activity is decreased in this group of older adults with bipolar disorder undergoing pharmacological treatment. The absence of a group of unmedicated bipolar patients and the non-uniform pattern of treatment do not allow us to say whether this reduction is due to characteristics of bipolar illness itself or an influence of the therapeutic drugs in use

Toll-like receptor 4 (TLR4), a key member of the TLR family, has been well characterized by its function in the induction of inflammatory products of innate immunity. However, the involvement of TLR4 in a variety of apoptotic events by an unknown mechanism has been the focus of great interest. Our investigation found that TLR4 promoted apoptotic signalling by affecting the glycogen synthase kinase-3β (GSK-3β) pathway in a serum-deprivation- induced apoptotic paradigm. Serum deprivation induces GSK-3β activation in a pathway that leads to subsequent cell apoptosis. Intriguingly, this apoptotic cascade is amplified in presence of TLR4 but greatly attenuated by β-arrestin 2, another critical molecule implicated in TLR4-mediated immune responses. Our data suggest that the association of β-arrestin 2 with GSK-3β contributes to the stabilization of phospho-GSK-3β, an inactive form of GSK-3β. It becomes a critical determinant for the attenuation of TLR4-initiated apoptosis by β-arrestin 2. Taken together, we demonstrate that the TLR4 possesses the capability of accelerating GSK-3β activation thereby deteriorating serum-deprivation-induced apoptosis; β-arrestin 2 represents an inhibitory effect on the TLR4-mediated apoptotic cascade, through controlling the homeostasis of activation and inactivation of GSK-3β.

Les modifications post-traductionnelles (MPTs) permettent un haut degré de régulation de l'expression des gènes en générant une diversité fonctionnelle au niveau du protéome. Dans le système nerveux, les MPTs régulent entre autres des facteurs de transcription permettant une adaptation rapide à un microenvironnement dynamique. Dans ce contexte, je me suis concentrée sur l’étude des Glycogène Synthase Kinases 3 (GSK3s). Elles sont au centre de la régulation de nombreuses voies de signalisation et contrôlent la stabilité de multiples cibles par phosphorylation. Au cours du développement du cerveau, les kinases GSK3 contrôlent la balance entre la prolifération et la différenciation. La dérégulation de l'activité des kinases GSK3 a un rôle clé dans les maladies neurodégénératives du cerveau. En revanche, le rôle important de ces kinases au cours du développement rétinien ainsi que dans les maladies neurodégénératives rétiniennes reste une question ouverte.L'objectif de ma thèse était d'étudier le rôle de ces kinases au cours du développement et de l'homéostasie rétinienne. J’ai montré que l'absence totale de Gsk3α et de Gsk3β très tôt au cours du développement rétinien entraîne une microphtalmie chez l'adulte. Les deux kinases jouent des rôles redondants puisque l'expression d'un seul allèle Gsk3 est suffisante pour prévenir le phénotype de microphtalmie. Cependant, une analyse phénotypique approfondie dans ce contexte génétique (un seul allèle Gsk3) a révélé une forte augmentation du nombre de cellules ganglionnaires déplacées (dRGCs) dans la couche nucléaire interne, associée à une modification des projections axonales des cellules ganglionnaires dans le cerveau par rapport aux contrôles. Dans l’ensemble, ces données suggèrent que les kinases GSK3s sont essentielles au maintien des progéniteurs rétiniens et sont impliquées dans la genèse des dRGCs. Compte tenu du très faible nombre de dRGCs en conditions normales, la fonction de ces cellules a été très peu étudiée à ce jour. Le modèle génétique que j’ai développé offre par conséquent un modèle de choix pour étudier l’ontogenèse et la fonction de ces cellules.Mes travaux de thèse se sont ensuite concentrés sur le rôle de GSK3 dans les photorécepteurs. En effet, des défauts de développement ou leur mort est l’une des principales causes de dégénérescence rétiniennes. Afin de mieux comprendre la fonction de ces kinases dans la maintenance des photorécepteurs, j'ai donc utilisé des souris invalidées de manière conditionnelle pour Gsk3α et Gsk3β spécifiquement dans les précurseurs des photorécepteurs. L’absence de GSK3 conduit à une altération de la maturation et de la fonction des photorécepteurs, suivie de leur dégénérescence. J’ai alors combiné des analyses transcriptomiques et des approches in vitro pour élucider les mécanismes sous-jacents. Mes données m’ont conduit à proposer un modèle selon lequel l’absence de GSK3 dans les photorécepteurs conduit à des défauts de phosphorylation de NRL (facteur de transcription nécessaire au développement des photorécepteurs de type bâtonnet), augmentant sa stabilité. Cette dérégulation post-traductionnelle conduit à la diminution d’expression d'un sous-ensemble de gènes cibles de NRL, co-régulés par CRX, et impliqués dans le développement et l'homéostasie des photorécepteurs. Cette dérégulation conduirait alors à la dégénérescence des photorécepteurs observée dans les mutants GSK3. Ce travail suggère donc que GSK3 joue un rôle essentiel dans la régulation de NRL pour contrôler la maturation et l'homéostasie des photorécepteurs. De telles données suggèrent également que ce mécanisme de régulation pourrait être déficient chez les patients atteints de rétinites pigmentaires dues à des mutations de NRL empêchant sa phosphorylation par GSK3. / Post-translational modifications (PTMs) allow a higher degree of regulation for the control of gene expression by generating functional diversity at the proteome level. In the central nervous system, PTMs regulate stability or activity of transcription factors allowing a rapid response to external signals and a quick adaptation to a dynamic cellular microenvironment. In this context, I focused on the ubiquitously expressed and highly conserved Glycogen Synthase Kinases 3 (GSK3s). They are at the crossroad of multifunctional signalling pathways. During mammalian brain development, GSK3 kinases control the balance between proliferation and differentiation. Deregulation of GSK3 kinases activity has also a key role in neurodegenerative diseases by causing the accumulation/aggregations of proteins causing neuronal cell death. Drugs targeting GSK3s hold a lot of promises to treat such diseases. Whether these kinases are also important during retinal development and involved in retinal diseases remains an open question. Several studies suggest the importance of regulating GSK3 function in photoreceptor under pathological conditions. Therefore, the main objective of my PhD was to investigate the role of these kinases during photoreceptor development and homeostasis. To better understand the role of these two kinases during retinal development and to highlight potential differences with the developing brain, we also investigated their function in the control of the balance between proliferation and differentiation of retinal progenitors. To achieve my work, I used conditional knockout mice for Gsk3α and Gsk3β specifically deleted either in photoreceptor precursors or in retinal progenitors during early development. The lack of GSK3 kinases in photoreceptor precursors led to impaired photoreceptor maturation and function followed by their degeneration. Transcriptomic analysis (RNAseq) 6, 10 and 14 days postnatally prior degeneration revealed several genes downregulated belonging to biological processes involved in eye development and visual functions. Among them, the expression of the transcription factor Nrl that is required for rod photoreceptor development was decreased. Astonishingly, NRL expression was highly increased at protein level. By in vitro approaches, I demonstrated that GSK3-dependent phosphorylation regulates NRL protein stability. Despite such increase, a large number of NRL target genes were downregulated leading to impaired photoreceptor maturation and function. Surprisingly, a vast majority of these downregulated genes were also target genes for CRX, another transcription factor working in synergy with NRL. This work demonstrates that PTMs of NRL play a critical role in fine tuning the expression of a subset of genes involved photoreceptor development and homeostasis. Such findings could allow the development of innovative therapeutic strategies for retinal dystrophies. The functional characterisation of GSK3 in the course of retinal development by invalidating both Gsk3α and Gsk3β in retinal progenitors early during development revealed their requirement for controlling cell cycle exit and neuronal differentiation. Indeed, the complete lack of Gsk3α and Gsk3β led to microphtalmia in adults. Interestingly, the expression of only one Gsk3 allele was enough to rescue the phenotype. However, further analysis revealed a large number of displaced ganglion cells in the inner nuclear layer. The function of these cells remains to be determined, but their timing of production corresponds to other ganglion cells. Strikingly, these displaced ganglion cells project in distinct brain regions than normal ganglion cells. Therefore, our work could provide the first step toward determining the function of the displaced ganglion cells, which appear at low number in wildtype but whose function remains to be clarified.

Thesis (MScMedSc)--University of Stellenbosch, 2011. / ENGLISH ABSTRACT: INTRODUCTION: Glycogen synthase kinase-3 (GSK-3) is a serine-threonine protein kinase that was first discovered as a regulator of glycogen synthase thus playing a role in glycogen synthesis (Embi et al. 1980). GSK-3 has also been shown to down regulate the expression of SERCA-2a (a calcium ATPase pump) thus playing a role in myocardial contractility (Michael et al. 2004). However, SERCA-2a activity is regulated by phospholamban (PLM) and sarcolipin (SLN) (Asahi et al. 2003). GSK-3 is constitutively active in cells and can be acutely inactivated by insulin through phosphorylation by PKB/Akt. However, GSK-3 is known to phosphorylate and inhibit IRS-1 protein, thus disrupting insulin signaling (Eldar-Finkelman et al. 1996). In addition, abnormally high activities of GSK-3 protein has been implicated in several pathological disorders which include type 2 diabetes, neuron degenerative and affective disorders (Eldar-Finkelman et al 2009). This led to the development of new generations of inhibitors with specific clinical implications to treat these diseases (Martinez 2008). GSK-3 inhibition has been shown to improve insulin and blood glucose levels and to be cardioprotective during ischemia/reperfusion (Nikoulina et al. 2002; Kumar et al. 2007). AIMS: To determine whether myocardial GSK-3 protein and its substrate proteins are dysregulated in obesity and insulin resistance, and whether a specific GSK-3 inhibitor can prevent or reverse the cardiovascular pathology found in obese and insulin resistant animals. OBJECTIVES: To correlate the alterations in expression and activation of GSK-3 protein in a well characterised rat model of obesity coupled to insulin resistance with: i) myocardial contractile dysfunction and an inability of hearts to withstand ischemia/reperfusion, ii) the activation and expression of phospholamban and SERCA-2a in the sarcoplasmic reticulum, iii) the activation of intermediates (IRS-1, IRS-2 and PKB/Akt) that lie upstream in the activation pathway of GSK-3 and iv) to determine the effects of inhibition of GSK-3 on the abovementioned parameters. METHODS: Age and weight matched male Wistar rats (controls and diet induced obese (DIO) animals) were used in the present study. Controls were fed normal rat chow, while DIOs were fed a rat chow diet supplemented with sucrose and condensed milk, for 8 or 16 weeks. Half of each group of animals were treated with the GSK-3 inhibitor for 4 weeks (from 12 to 16 weeks). After the feeding and treatment period, animals were weighed, sacrificed, hearts removed and freeze clamped immediately or perfused with Krebs-Henseleit buffer and subjected to low flow ischemia (25 min) followed by 30 min reperfusion. Biometric (body weight, intraperitoneal fat, ventricular weight and tibia length) and biochemical (fasting blood glucose and insulin levels) parameters were determined. Expression of GSK-3, PKB/Akt, IRS-1, IRS-2, SERCA-2a and Phospholamban were determined by Western blotting. Ca2+ ATPase activity was determined spectrophotometrically. RESULTS: At both 8 and 16 weeks DIO animals were significantly bigger than control animals and this was associated with increased intraperitoneal fat in DIOs. In DIO animals: IRS-1 was downregulated at 8 weeks and both IRS-1 and IRS-2 as well as PKB/Akt at 16 weeks. There was an increased tendency of GSK-3 expression at both 8 and 16 weeks in DIO animals while SERCA-2a was severely downregulated from 8 weeks onwards and associated with lower Ca2+-ATPase activity. PLM expression was upregulated but its phosphorylation was attenuated. At 16 weeks, baseline heart rate (225 vs 275 in control, P<0.0001, n=6) and rate pressure product (21000 vs 30000 in control, P=0.019, n=6) were significantly lower in hearts from DIO animals. Functional recovery was unchanged but the time to ischemic contracture development was increased (11.6±0.4 control vs 16.2±0.5 min DIO, P<0.01, n=6). Treatment had no effect on total GSK-3 expression. However, GSK-3 phosphorylation was significantly increased in treated controls, while there was no significant difference in DIO animals. However, there was a tendency for an increased GSK-3 phosphorylation in treated DIO animals. GSK-3 inhibitor, improved hypertrophy in DIO animals, while it led to its development in control animals. GSK-3 inhibitor improved IRS-2 expression in both control and DIO animals while it had no effect on IRS-1 and SERCA-2a expression and activity. However, GSK-3 inhibition increased PKB/Akt and phospholamban phosphorylation in DIO animals. CONCLUSION: These findings show that high calorie diet as well as imbalance between energy intake and expenditure lead to the development of obesity and insulin resistance in male Wistar rats. We showed that GSK-3 and its substrate proteins are dysregulated in obesity and insulin resistance. The reduced SERCA-2a expression at baseline may have a negative impact on cardiac function. By treating the animals with GSK-3 inhibitor, we showed that GSK-3 protein may not be responsible for changes seen at baseline. The decreased IRS-1 and SERCA-2a expression may have been caused by a different mechanism other than the actions of GSK-3. However, according to this study, GSK-3 may play a role in regulation of IRS-2 expression but not in IRS-1. Increased PKB/Akt phosphorylation may contribute to the GSK-3 inhibition. In addition, GSK-3 inhibition may reverse cardiac hypertrophy in DIO animals, thus acting as a negative regulator of hypertrophy. / AFRIKAANSE OPSOMMING: Inleiding: Glikogeen sintase kinase-3 (GSK-3), 'n serien/threonien proteïen kinase, is oorspronklik ontdek as 'n rolspeler in glikogeen sintese, aangesien dit 'n reguleerder van glikogeen sintase is (Embi et al.1980). Intussen is dit ook bevind dat GSK-3 die uitdrukking van SERCA-2a ('n kalsium ATPase pomp) kan afreguleer en dus sodoende 'n rol speel in miokardiale kontraktiliteit (Michael et al. 2004). Die aktiwiteit van SERCA-2a kan egter ook gereguleer word deur fosfolamban (PLM) en sarkolipin (Asahi et al. 2003). GSK-3 is deurgaans aktief, maar kan tydelik geïnaktiveer word onder kondisies van insulien stimulasie deur PKB/Akt gemedieerde fosforilering. Aan die ander kant is dit bekend dat GSK-3 die IRS-1 proteïen kan fosforileer om dus sodoende insulien sein-transduksie af te reguleer (Eldar-Finkelman et al. 1996). Daarmee saam is abnormaal hoë vlakke van GSK-3 aktiwiteit geassosieer met verskeie patologiese versteurings, insluitend tipe 2 diabetes, neuron degeneratiewe en affektiewe versteurings (Eldar-Finkelman et al. 2009). Daar is dus nuwe generasies GSK-3 inhibitore ontwikkel met die kliniese potensiaal om hierdie patologieë te behandel (Martinez 2008). Dit is al bevind dat GSK-3 inhibisie geassosieer kan word met beide die normalisering van plasma insulien- en glukose vlakke, asook kardiobeskerming in die konteks van iskemie/herperfusie (Nikoulina et al. 2002; Kumar et al. 2007). Doelwitte: Om te bepaal of GSK-3 proteïen en sy substraat proteïene gedisreguleer is onder kondisies van obesiteit en insulien weerstandigheid, asook om vas te stel of 'n spesifieke GSK-3 inhibitor die kardiovaskulêre patologie wat gevind word in obese en insulien weerstandige diere kan verhoed of omkeer. Mikpunte: Om veranderinge in uitdrukking en aktiwiteit van GSK-3 proteïen in 'n goed gekarakteriseerde rotmodel van obesiteit, gekoppel aan insulien weerstandigheid, te korreleer met die volgende: i) miokardiale kontraktiele disfunksie en onvermoë om kardiale iskemie/herperfusie besering te weerstaan, ii) aktivering en uitdrukking van PLM en SERCA-2a in die sarkoplasmiese retikulum, iii) die aktivering van intermediêres wat proksimaal geleë is in die insulienseintransduksiepad van GSK-3 (IRS-1, IRS-2 en PKB/Akt) en iv) om die effek van behandeling met 'n spesifieke inhibitor van GSK-3 op die bogenoemde punte te bepaal. Metodes: Ouderdoms- en gewigsgepaarde manlike Wistar rotte (kontrole en dieet geïnduseerde obees (DIO) diere) is in die studie gebruik. Kontrole diere was normale rotkos gevoer, terwyl die DIO diere op 'n dieet van rotkos aangevul met sukrose en kondensmelk geplaas is vir 'n periode van 8 of 16 weke. Helfte van die diere van elke groep is behandel met die GSK-3 inhibitor vir 4 weke (vanaf week 12 tot 16). Na afloop van die voer- en behandelingsperiode is die diere geweeg, doodgemaak en die harte verwyder om dan of onmiddelik gevriesklamp te word, of retrograad geperfuseer te word met Krebs-Hensleit buffer. Ex vivo geperfuseerde harte is dan blootgestel aan 25 minute lae vloei iskemie gevolg deur 30 minute herperfusie. Biometriese (liggaamsgewig, intraperitoneale vet, ventrikulêre gewig en tibia lengte) en biochemiese (vastende bloedglukose en -insulien vlakke) parameters is telkens bepaal. Western klad tegnieke is gebruik om die uitdrukking en fosforilering van GSK-3, PKB/Akt, IRS-1, IRS-2, SERCA-2a en PLM te bepaal. Ca2+-ATPase aktiwiteit is spektrofotometries bepaal. Resultate: Na beide 8 en 16 weke was die DIO diere beduidend swaarder as die kontrole diere. Hierdie gewigstoename was geassosieer met meer intraperitoneale vet in die DIO diere. Verder, in die DIO diere was IRS-1 afgereguleer na 8 weke, terwyl beide IRS-1 en IRS-2 asook PKB/Akt afgereguleer was na 16 weke. GSK-3 uitdrukking het 'n neiging getoon om toe te neem na beide 8 en 16 weke in die DIO diere, terwyl SERCA-2a beduidend afgereguleer was reeds vanaf 8 weke, geassosieer met laer Ca2+-ATPase aktiwiteit. PLM uitdrukking het toegeneem en die fosforilering daarvan was verlaag. Op 16 weke was die basale harttempo (225 vs 275 in die kontrole groep, P<0.0001, n=6) en tempo druk produk (21000 vs 30000 in die kontrole groep, P=0.019, n=6) betekenisvol laer in die DIO diere. Funksionele herstel het onveranderd gebly, alhoewel die tyd tot iskemiese kontraktuur toegeneem het in die DIO groep (kontrole: 11.6±0.4 min vs DIO: 16.2±0.5 min, P<0.01, n=6). Toediening van die inhibitor het geen effek op totale GSK-3 uitdrukking gehad nie. Fosforilering van GSK-3 was egter wel beduidend verhoog in die behandelde kontrole diere, terwyl daar geen verskille in die DIO groep was nie. Die fosforilering van GSK-3 het wel geneig na 'n toename in die behandelde DIO diere. Die GSK-3 inhibitor het kontrasterende effekte op hipertrofie gehad: dit het dit omgekeer in die DIO groep, maar veroorsaak in die kontrole diere. Daarmee saam het die inhibitor die uitdrukking van IRS-2 in beide DIO en kontrole diere gestimuleer, maar geen effek op IRS-1 en SERCA-2a uitdrukking en aktiwiteit gehad nie. GSK-3 inhibisie het wel PKB/Akt en PLM fosforilering in die DIO diere verhoog. Gevolgtrekking: Hierdie bevindinge toon dat 'n hoë kalorie dieet, tesame met 'n wanbalans tussen energie inname en verbruiking, lei tot die ontwikkeling van obesiteit en insulien weerstand in manlike Wistar rotte. Die studie het ook getoon dat GSK-3 en sy substraat proteïene wel gedisreguleer is in obesiteit en insulien weerstandigheid. Die verlaagde basale uitdrukking van SERCA-2a mag dalk 'n negatiewe impak hê op kardiale funksie. Behandeling van die diere met 'n GSK-3 inhibitor het getoon dat GSK-3 moontlik nie verantwoordelik is vir die basislyn veranderinge nie. Die afname in IRS-1 en SERCA-2a uitdrukking kan moontlik toegeskryf word aan ander meganismes buiten die effekte van GSK-3. Hierdie studie toon wel dat GSK-3 moontlik 'n rol speel in die regulering van die uitdrukking van IRS-2, maar nie IRS-1 nie. Verhoogde PKB/Akt fosforilering mag dalk bydra tot die inhibisie van GSK-3. Daarmee saam blyk dit dat GSK-3 inhibisie hipertrofie kan omkeer in DIO diere, om dan sodoende op te tree as 'n negatiewe reguleerder van hipertrofie, maar in normale kontrole diere, hipertrofie in die hand werk. / South African Medical Research Council / University of Stellenbosch, Dept. of medical Physiology

A Doença de Alzheimer (DA) é uma desordem neurodegenerativa progressiva que causa comprometimento cognitivo e demência. O diagnóstico é baseado em parâmetros clínicos, mas sua confirmação é post-mortem, após avaliação patológica durante a autópsia. Os tratamentos disponíveis para a DA são os inibidores da colinesterase (IChEs) e os antagonistas de receptores de N-metil-D-aspartato (NMDA), sendo que os IChEs compõe o principal grupo. Diversos estudos tem mostrado um efeito neuroprotetor dos IChEs, levando a alterações na patogênese da DA. Avaliar e mensurar essas alterações são papeis atribuídos aos biomarcadores. Neste sentido podemos destacar a fosfolipase A2 (PLA2), a principal responsável pelo metabolismo de fosfolípides de membrana, e que tem sido achada diminuída na DA, assim como a glicogênio sintase-quinase (GSK), responsável pela fosforilação da proteína Tau, que é um dos processos alterados na DA. O objetivo deste trabalho foi avaliar o efeito do tratamento com IChE sobre a atividade da PLA2 e expressão da GSK3B em plaquetas de 30 pacientes com DA após 3 e 6 meses de tratamento. Como grupo controle foram investigados 42 individuos idosos sem doença neurodegenerativa. Encontramos nos pacientes com DA antes do tratamento uma diminuição da atividade da iPLA2 quando comparada ao grupo controle. Após três e seis meses de tratamento a PLA2 aumentou, voltando ao nível dos controles. Os pacientes que apresentaram um aumento maior da iPLA2 apos 3 meses de tratamento apresentaram melhora cognitiva mais marcante após seis meses de tratamento, avaliado pelo CAMCOG. Apos 6 meses de tratamento encontramos um inativação da GSK3B, medida por um aumento em sua forma fosforilada. Nossos resultados sugerem que o donepezil apresenta propriedades modificadoras na doença de Alzheimer, e ainda que a medida da atividade da iPLA2 poderia ser usada como marcador de resposta terapêutica ao donepezil e, possivelmente, a outros IChEs, na doença de Alzheimer / Alzheimer\'s disease (AD) is a progressive neurodegenerative disorder that causes dementia and cognitive impairment. The Diagnosis is based on clinical parameters, but confirmation is post-mortem after pathologic evaluation during autopsy. The treatments available for AD are cholinesterase inhibitors (IChEs) and N-methyl-D-aspartate (NMDA) antagonists. The main group comprises the IChEs. Several studies have shown a neuroprotective effect of IChEs, leading to alterations in the pathogenesis of AD. Evaluate and measure these changes are assigned to biomarkers. In this regard we can highlight the phospholipase A2 (PLA2) the main enzyme in membrane phospholipids metabolism and that has been found decreased in AD as well as Glycogen Synthase kinase (GSK), a major responsible for tau phosphorylation which is one processes altered in AD. The objective of this study was to evaluate the effect of treatment with IChE on PLA2 activity and GSK3B expression in platelet of 30 AD patients after 3 and 6 months of treatment. The control group comprised 42 elderly individuals without neurodegenerative disease The results obtained were a decreased iPLA2 activity in patients with AD before treatment as compared to controls. After 3 and 6 months of treatment, we observed a significant increase in iPLA2 activity, restoring enzymatic activity similar to that observed among control. The patients who showed higher iPLA2 activity in the first three months were those showing cognitive improvement after six months of treatment, measured by CAMCOG. After 6 months of treatment a GSK3B inactivation were found, measured by an increase in its phosphorylated form. Our results suggest that donepezil present modifying properties in Alzheimer disease and that iPLA2 activity measurement could be used as a marker of therapeutic response to donepezil and possibly other IChEs in Alzheimer\'s disease

A Doença de Alzheimer (DA) é um transtorno progressivo que acomete o Sistema Nervoso Central, causando demência em idosos. A doença leva a uma diminuição da memória, dificuldade no raciocínio e pensamento e alterações comportamentais. A fisiopatologia da doença corresponde ao aumento na concentração do peptídeo -amilóide com consequente deposição e formação da placa amiloide; e também ao aparecimento dos emaranhados neurofibrilares, que são agregados de proteína tau hiperfosforilada. A enzima glicogênio sintase cinase 3 beta (GSK-3) está diretamente envolvida nos dois processos e, por isso, a busca por novos inibidores dessa enzima é uma importante estratégia terapêutica para o tratamento da doença. Neste trabalho utilizou-se a triagem virtual em 7 bancos de dados de moléculas aplicando cinco diferentes estratégias in silico, através de planejamento de fármacos baseado em ligantes e baseado em estrutura, combinada com estudos in silico de farmacocinética, toxicidade e atividade biológica, seguido de posteriores ensaios de inibição enzimática in vitro. Obteve-se três compostos pela metodologia de farmacóforo, (Estratégia 3) dos quais dois deles demonstraram atividade inibitória interessante para GSK-3, na faixa de micromolar. A partir das outras quatro estratégias foram selecionados 16 compostos que futuramente serão também testados utilizando o mesmo protocolo de ensaio in vitro aqui utilizado. / Alzheimer\'s disease (AD) is a progressive disorder that affects the Central Nervous System, causing dementia in the elderly. The disease leads to decreased memory, difficulty in reasoning and thinking, and behavioral changes. The pathophysiology of the disease corresponds to the increase in -amyloid peptide concentration with consequent deposition and formation of the amyloid plaque and to the appearance of neurofibrillary tangles, which are aggregates of hyperphosphorylated tau protein. The enzyme glycogen synthase kinase-3 beta (GSK-3) is directly involved in both processes and, therefore, the search for new inhibitors of this enzyme is an important therapeutic strategy for the treatment of the disease. In this work, we used virtual screening in 7 molecule databases applying five different in silico strategies, using the ligand-based and structure-based drug design methodologies, combined with in silico studies of pharmacokinetics, toxicity and biological activity, followed by subsequent assays enzymatic inhibition in vitro. We obtained three compounds by the pharmacophore methodology (Strategy 3) of which two of them demonstrated interesting inhibitory activity for GSK-3 in the micromolar range. From the other four strategies, 16 compounds were selected which in future will also be tested using the same in vitro assay protocol used here.

A Doença de Alzheimer (DA) é uma desordem neurodegenerativa progressiva que causa comprometimento cognitivo e demência. O diagnóstico é baseado em parâmetros clínicos, mas sua confirmação é post-mortem, após avaliação patológica durante a autópsia. Os tratamentos disponíveis para a DA são os inibidores da colinesterase (IChEs) e os antagonistas de receptores de N-metil-D-aspartato (NMDA), sendo que os IChEs compõe o principal grupo. Diversos estudos tem mostrado um efeito neuroprotetor dos IChEs, levando a alterações na patogênese da DA. Avaliar e mensurar essas alterações são papeis atribuídos aos biomarcadores. Neste sentido podemos destacar a fosfolipase A2 (PLA2), a principal responsável pelo metabolismo de fosfolípides de membrana, e que tem sido achada diminuída na DA, assim como a glicogênio sintase-quinase (GSK), responsável pela fosforilação da proteína Tau, que é um dos processos alterados na DA. O objetivo deste trabalho foi avaliar o efeito do tratamento com IChE sobre a atividade da PLA2 e expressão da GSK3B em plaquetas de 30 pacientes com DA após 3 e 6 meses de tratamento. Como grupo controle foram investigados 42 individuos idosos sem doença neurodegenerativa. Encontramos nos pacientes com DA antes do tratamento uma diminuição da atividade da iPLA2 quando comparada ao grupo controle. Após três e seis meses de tratamento a PLA2 aumentou, voltando ao nível dos controles. Os pacientes que apresentaram um aumento maior da iPLA2 apos 3 meses de tratamento apresentaram melhora cognitiva mais marcante após seis meses de tratamento, avaliado pelo CAMCOG. Apos 6 meses de tratamento encontramos um inativação da GSK3B, medida por um aumento em sua forma fosforilada. Nossos resultados sugerem que o donepezil apresenta propriedades modificadoras na doença de Alzheimer, e ainda que a medida da atividade da iPLA2 poderia ser usada como marcador de resposta terapêutica ao donepezil e, possivelmente, a outros IChEs, na doença de Alzheimer / Alzheimer\'s disease (AD) is a progressive neurodegenerative disorder that causes dementia and cognitive impairment. The Diagnosis is based on clinical parameters, but confirmation is post-mortem after pathologic evaluation during autopsy. The treatments available for AD are cholinesterase inhibitors (IChEs) and N-methyl-D-aspartate (NMDA) antagonists. The main group comprises the IChEs. Several studies have shown a neuroprotective effect of IChEs, leading to alterations in the pathogenesis of AD. Evaluate and measure these changes are assigned to biomarkers. In this regard we can highlight the phospholipase A2 (PLA2) the main enzyme in membrane phospholipids metabolism and that has been found decreased in AD as well as Glycogen Synthase kinase (GSK), a major responsible for tau phosphorylation which is one processes altered in AD. The objective of this study was to evaluate the effect of treatment with IChE on PLA2 activity and GSK3B expression in platelet of 30 AD patients after 3 and 6 months of treatment. The control group comprised 42 elderly individuals without neurodegenerative disease The results obtained were a decreased iPLA2 activity in patients with AD before treatment as compared to controls. After 3 and 6 months of treatment, we observed a significant increase in iPLA2 activity, restoring enzymatic activity similar to that observed among control. The patients who showed higher iPLA2 activity in the first three months were those showing cognitive improvement after six months of treatment, measured by CAMCOG. After 6 months of treatment a GSK3B inactivation were found, measured by an increase in its phosphorylated form. Our results suggest that donepezil present modifying properties in Alzheimer disease and that iPLA2 activity measurement could be used as a marker of therapeutic response to donepezil and possibly other IChEs in Alzheimer\'s disease

Le diabète est une maladie chronique avec une progression alarmante. L’insuline-résistance et la diminution de la masse fonctionnelle des cellules beta, associée à l'inflammation des îlots, sont les principaux défauts impliqués dans la pathogenèse du diabète de type 2 (DT2). La compréhension des mécanismes impliqués dans l'inflammation des îlots pancréatiques, et l'identification de cibles moléculaires à visée anti-inflammatoire, sont des approches intéressantes pour le traitement du diabète. La glycogène synthase kinase 3 (GSK3), est une sérine-thréonine kinase qui régule des fonctions cellulaires essentielles. Cette enzyme a été récemment décrite comme un régulateur important de l'inflammation dans différentes conditions pathologiques. Cependant, l'implication potentielle de GSK3beta dans l'inflammation des îlots au cours du diabète reste inexplorée. Le but de ce travail était d'étudier l'implication de GSK3beta dans l'inflammation des îlots pancréatiques et d'évaluer l'impact de l'inhibition de GSK3beta dans l’amélioration de l’hyperglycémie du rat diabétique Goto-Kakizaki. Le rat Goto-Kakizaki (GK) est un modèle spontané de DT2, avec une hyperglycémie chronique apparaissant au sevrage, une masse beta cellulaire réduite et une altération profonde de la sécrétion d'insuline en réponse au glucose. Peu après le sevrage, l'inflammation se développe dans les îlots du rat GK et participe au dysfonctionnement des cellules beta. Nous avons traité les rat GK mâles avec du chlorure de lithium (LiCl), un inhibiteur de GSK3. Le traitement chronique de jeunes rats GK a permis d’éviter l’installation de l’hyperglycémie chronique qui se développe normalement dans ce modèle chez les adultes. A la fin du traitement, la glycémie basale des rats GK traités par le LiCl était fortement réduite, en comparaison avec celle des rats GK non traités. Ces améliorations étaient associées à une réduction de l'expression des cytokines et des chimiokines pro-inflammatoires dans les îlots. L’inhibition de GSK3 a également diminué la fibrose des îlots et rétabli partiellement la sensibilité à l’insuline et la sécrétion d'insuline induite par le glucose chez les rats GK. De plus, des études ex vivo sur des îlots humains et des îlots de rats Wistar, exposés à un environnement inflammatoire en culture, ont révélé l'implication directe de GSK3 dans la réponse inflammatoire autonome des îlots. Ceci était entre autres associée à l’activation du facteur de transcription STAT3. En conclusion, nous montrons pour la première fois que GSK3beta est impliquée dans l’inflammation des îlots pancréatiques humains et de rongeurs. L’inhibition de GSK3beta atténue fortement l’inflammation insulaire, et prévient l’installation de l’hyperglycémie chronique chez le rat GK. L’ensemble des résultats de ce travail nous permet de proposer GSK3beta comme une cible potentielle pour le développement de traitements anti-inflammatoires dans le contexte du diabète de type 2 / Diabetes Mellitus (DM) is a chronic disabling disease with epidemic dimension. It is now established that islet inflammation is associated with defective functional beta cell mass in type 2 diabetes. The understanding of the mechanisms that govern diabetes-associated inflammation in pancreatic islets, and the identification of molecular targets to dampen inflammation are important steps to address this pathological condition. GK rat is a spontaneous model of type 2 diabetes with impaired beta cell function and mass, closely associated with islet inflammation. Glycogen Synthase Kinase 3 (GSK3) is a multi-tasking serine-threonine kinase which regulates crucial cellular functions. In recent years, GSK3beta has been found to be an important regulator of inflammation in different diseased conditions. However, the potential role of GSK3beta in the context of islet inflammation remains unexplored. In this study, we tested the potential of lithium, an inhibitor of GSK3, in improving islet inflammation and glucose metabolism in the GK rat. In vivo, treatment of young GK rats prevented the development of overt diabetes which normally occurs in adult individuals. Lithium improved the glycemic status of the GK rats after few weeks of treatment. At the end of the protocol, GK rats treated with lithium had a blood glucose levels that were significantly lower than that of age-matched untreated GK rats, which were overtly diabetic at this stage. Lithium treatment resulted in reduced expression of pro-inflammatory cytokines and chemokines, decreased fibrosis and reduced macrophage infiltration in the islets. Lithium partially restored the pancreatic insulin content, the insulin sensitivity and the glucose induced insulin secretion in the GK rats. Moreover, ex vivo studies in non-diabetic human and rat islets exposed to inflammatory environment in culture, revealed the direct implication of GSK3 in the islet autonomous inflammatory response. Moreover, we showed that GSK3 controls the islet inflammatory response at least in part by regulating the activity of the pro-inflammatory transcription factor STAT3. Taken together, our results identified GSK3 as a viable target to treat diabetes-associated inflammation, and could have potential clinical application in the treatment of diabetes and metabolic syndrome